In last trading session, Avadel Pharmaceuticals plc (NASDAQ:AVDL) saw 0.56 million shares changing hands with its beta currently measuring 1.33. Company’s recent per share price level of $11.15 trading at -$0.02 or -0.18% at ring of the bell on the day assigns it a market valuation of $1.07B. That closing price of AVDL’s stock is at a discount of -71.21% from its 52-week high price of $19.09 and is indicating a premium of 6.64% from its 52-week low price of $10.41. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.48 million shares which gives us an average trading volume of 1.18 million if we extend that period to 3-months.
For Avadel Pharmaceuticals plc (AVDL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 8 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.04 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avadel Pharmaceuticals plc (NASDAQ:AVDL) trade information
Upright in the red during last session for losing -0.18%, in the last five days AVDL remained trading in the red while hitting it’s week-highest on Friday, 11/22/24 when the stock touched $11.15 price level, adding 8.76% to its value on the day. Avadel Pharmaceuticals plc’s shares saw a change of -21.03% in year-to-date performance and have moved -4.37% in past 5-day. Avadel Pharmaceuticals plc (NASDAQ:AVDL) showed a performance of -13.63% in past 30-days. Number of shares sold short was 8.81 million shares which calculate 6.21 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 7.08% to its current value. Analysts have been projecting 9 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would jump 19.28% in reaching the projected high whereas dropping to the targeted low would mean a gain of 19.28% for stock’s current value.
Avadel Pharmaceuticals plc (AVDL) estimates and forecasts
Statistics highlight that Avadel Pharmaceuticals plc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -30.09% of value to its shares in past 6 months, showing an annual growth rate of 76.00% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 512.99% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 52.7M for the same. And 6 analysts are in estimates of company making revenue of 58.71M in the next quarter. Company posted 19.45M and 27.18M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.78% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 76.06% while estimates for its earnings growth in next 5 years are of 15.00%.
Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s Major holders
Insiders are in possession of 4.77% of company’s total shares while institution are holding 80.07 percent of that, with stock having share float percentage of 84.08%. Investors also watch the number of corporate investors in a company very closely, which is 80.07% institutions for Avadel Pharmaceuticals plc that are currently holding shares of the company. VIVO CAPITAL, LLC is the top institutional holder at AVDL for having 3.97 million shares of worth $55.85 million. And as of 2024-06-30, it was holding 4.332 of the company’s outstanding shares.
The second largest institutional holder is TRI LOCUM PARTNERS LP, which was holding about 1.19 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.2973 of outstanding shares, having a total worth of $16.72 million.
On the other hand, Vanguard Total Stock Market Index Fund and Janus Henderson Global Life Sciences Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 2.98 shares of worth $32.99 million or 3.10% of the total outstanding shares. The later fund manager was in possession of 2.67 shares on Sep 30, 2024 , making its stake of worth around $29.57 million in the company or a holder of 2.77% of company’s stock.
